Antibody mediated neutralization of myelin associated EphrinB3 accelerates CNS remyelination
Syed, Yasir A.
Franklin, Robin J. M.
Nave, Klaus- A.
Kotter, Mark R. N.
MetadataShow full item record
Syed, Y. A., Zhao, C., Mahad, D., Möbius, W., Altmann, F., Foss, F., Sentürk, A., et al. (2015). Antibody mediated neutralization of myelin associated EphrinB3 accelerates CNS remyelination. Acta Neuropathologica, 131 (2), 281-298. https://www.repository.cam.ac.uk/handle/1810/251430
This is the final version of the article. It was first available from Springer via http://dx.doi.org/10.1007/s00401-015-1521-1
Remyelination in multiple sclerosis (MS) lesions often remains incomplete despite the presence of oligodendrocyte progenitor cells (OPCs). Amongst other factors, successful remyelination depends on the phagocytic clearance of myelin debris. However, the proteins in myelin debris that act as potent and selective inhibitors on OPC differentiation and inhibit CNS remyelination remain unknown. Here, we identify the transmembrane signalling protein EphrinB3 as important mediator of this inhibition, using a protein analytical approach in combination with a primary rodent OPC assay. In the presence of EphrinB3, OPCs fail to differentiate. In a rat model of remyelination, infusion of EphrinB3 inhibits remyelination. In contrast, masking EphrinB3 epitopes using antibodies promotes remyelination. Finally, we identify EphrinB3 in MS lesions and demonstrate that MS lesion extracts inhibit OPC differentiation while antibody-mediated masking of EphrinB3 epitopes promotes it. Our findings suggest that EphrinB3 could be a target for therapies aiming at promoting remyelination in demyelinating disease.
Remyelination, EphrinB3, Oligodendrocytes, Multiple Sclerosis
This work was supported by the UK MS Society Grant ref: 941/11. MRNK held a NIHR Clinical Lectureship. KAN was supported by an ERC advanced award.
This record's URL: https://www.repository.cam.ac.uk/handle/1810/251430
Creative Commons Attribution 4.0 International License
Licence URL: http://creativecommons.org/licenses/by/4.0/